CTOs on the Move

Fog Pharmaceuticals

www.fogpharma.com

 
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.fogpharma.com
  • 100 Acorn Park Drive 6th Floor
    Cambridge, MA 02140, AB USA
  • Phone: 617.945.9510

Executives

Name Title Contact Details

Funding

Fog Pharmaceuticals raised $66M on 05/16/2018

Similar Companies

bioMASON

We build with carbon the same way nature does. Our biocement® materials are healthier for us and the Planet.

GenBio

ormed in 1994, GenBio is an experienced, fully integrated medical diagnostic company focused on infectious disease and autoimmune disease diagnostics. GenBio develops, manufactures and markets extensive lines of infectious disease and autoimmunity

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.

Globe Labs

Globe Labs Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exscientia

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We`ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.